GPAT vs GS vs JPM vs MS vs BAC

For growth investors, Morgan Stanley (MS) is the stronger pick with 11.

5% revenue growth year-over-year, versus -1. 4% for The Goldman Sachs Group, Inc. (GS). Bank of America Corporation (BAC) offers the better valuation at 14. 7x trailing P/E (12. 6x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.

7x versus GP-Act III Acquisition Corp. at 26. 4x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Morgan Stanley's 1. 88x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, The Goldman Sachs Group, Inc.

(GS) delivered a total return of +200. 5%, compared to +8. 5% for GP-Act III Acquisition Corp. (GPAT). Over 10 years, the gap is even starker: MS returned +854. 4% versus GPAT's +8. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), GP-Act III Acquisition Corp.

(GPAT) is the lower-risk stock at -0. 02β versus The Goldman Sachs Group, Inc. 's 1. 60β — meaning GS is approximately -7815% more volatile than GPAT relative to the S&P 500. On balance sheet safety, GP-Act III Acquisition Corp. (GPAT) carries a lower debt/equity ratio of 0% versus 5% for The Goldman Sachs Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Morgan Stanley (MS) is pulling ahead at 11.

5% versus -1. 4% for The Goldman Sachs Group, Inc. (GS). On earnings-per-share growth, the picture is similar: Morgan Stanley grew EPS 28. 3% year-over-year, compared to -12. 8% for GP-Act III Acquisition Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus 0. 0% for GP-Act III Acquisition Corp. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 0. 0% for GPAT. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Morgan Stanley's 1. 88x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 6x forward P/E versus 18. 0x for Morgan Stanley — 5. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BAC: 9. 1% to $61. 13.

In this comparison, BAC (2.

3% yield), MS (1. 9% yield), JPM (1. 9% yield), GS (1. 6% yield) pay a dividend. GPAT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, GP-Act III Acquisition Corp.

(GPAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 02)). The Goldman Sachs Group, Inc. (GS) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GPAT: +8. 5%, GS: +666. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GPAT is a small-cap quality compounder stock; GS is a large-cap quality compounder stock; JPM is a large-cap deep-value stock; MS is a large-cap quality compounder stock; BAC is a large-cap deep-value stock. GS, JPM, MS, BAC pay a dividend while GPAT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.